Association of Xba I allele (Xba I 44kb) of the human cytochrome P-450dbI (CYP2D6) gene in Japanese patients with idiopathic Parkinson’s disease

  • I. Kondo
  • I. Kanazawa
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Cytochrome P-450dbl gene (CYP2D6) Xba I genotypes were investigated in 43 unrelated healthy Japanese and 51 patients with idiopathic Parkinson’s disease (IPD), using genomic DNA hybridization analysis with a cDNA probe encoding cytochrome P- 450dbl. Restriction fragment length polymorphisms (RFLPs) were observed in both populations, but the frequencies of alleles detected by restriction enzyme Xba I differed significantly. The relative risk of IPD is 2.15 times greater for idividuals with a Xba I 44 kb allele compared to those without the allele (x2 = 4.149, d.f. = 1, p < 0.05). Furthermore, the relative risk of IPD is 6.32 times greater for the Xba I 44 kb homozygotes than the Xba I 29 kb homozygotes (x2 = 4.935, d.f. = 1, p < 0.05). These data suggest that the Xba I 44 kb allele of CYP2D6 is one of the genetic factors making humans susceptible to IPD acquisition.


Extensive Metabolizer Restriction Fragment Length Polymorph CYP2D6 Genotype Restriction Fragment Length Poly Defective Allele 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet ii: 1213–1215Google Scholar
  2. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S (1986) Environmental and genetic factors in the etiology of Parkinson’s disease. Adv Neurol 45: 299–306Google Scholar
  3. Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3835PubMedCrossRefGoogle Scholar
  4. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446PubMedCrossRefGoogle Scholar
  5. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allelespecific PCR amplification. Lancet 336: 529–532PubMedCrossRefGoogle Scholar
  6. Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23: 482–485PubMedGoogle Scholar
  7. Kunkel LM, Smith KD, Bother SH, Borgaonkar DS, Wachtel SS, Miller OJ, Breg WR, Jones HW, Rary JM (1977) Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 74: 1245–1249PubMedCrossRefGoogle Scholar
  8. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analogy synthesis. Science 219: 979–980PubMedCrossRefGoogle Scholar
  9. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii: 584–586Google Scholar
  10. Nakamura K, Goto F, Ray WA, McAllester CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephnytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408PubMedCrossRefGoogle Scholar
  11. Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W (1990) The dopanime transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain; resolution and identification of two distinct [3H]-GBR- 12935 binding proteins. Arch Biochem Biophys 276: 424–432PubMedCrossRefGoogle Scholar
  12. Shahi GS, Moochhala SM, Das NP (1989) Depression of the hepatic cytochrome P450 monooxygenase system by the neurotoxin l-methyl-4-phenyl-l,2,3,6- tetrahydropyridine (MPTP). Pharmacol Toxicol 64: 107–110PubMedCrossRefGoogle Scholar
  13. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P-450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85: 5240–5243PubMedCrossRefGoogle Scholar
  14. Southern EM (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98: 503–517PubMedCrossRefGoogle Scholar
  15. Yue QY, Bertilsson L, Dahl-Puustinen ML, Sawe J, Sjogvist F, Johansson I, Ingelman- Sundberg M (1989) Dissassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet ii: 870Google Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • I. Kondo
    • 1
  • I. Kanazawa
    • 2
  1. 1.Departments of Human Ecology and Genetics, Faculty of MedicineUniversity of the RyukyusOkinawaJapan
  2. 2.Department of Neurology, Institute of Clinical MedicineUniversity of TsukubaIbarakiJapan

Personalised recommendations